WO2005089317A3 - Immune response modifier formulations and methods - Google Patents

Immune response modifier formulations and methods Download PDF

Info

Publication number
WO2005089317A3
WO2005089317A3 PCT/US2005/008576 US2005008576W WO2005089317A3 WO 2005089317 A3 WO2005089317 A3 WO 2005089317A3 US 2005008576 W US2005008576 W US 2005008576W WO 2005089317 A3 WO2005089317 A3 WO 2005089317A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune response
response modifier
methods
sorbic acid
modifier formulations
Prior art date
Application number
PCT/US2005/008576
Other languages
French (fr)
Other versions
WO2005089317A2 (en
Inventor
Terri F Busch
Leo W Kueper Iii
Original Assignee
3M Innovative Properties Co
Terri F Busch
Leo W Kueper Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co, Terri F Busch, Leo W Kueper Iii filed Critical 3M Innovative Properties Co
Priority to ES05725623.2T priority Critical patent/ES2665342T3/en
Priority to US10/598,824 priority patent/US20070167479A1/en
Priority to JP2007504030A priority patent/JP4991520B2/en
Priority to CA2559607A priority patent/CA2559607C/en
Priority to AU2005222995A priority patent/AU2005222995B2/en
Priority to EP05725623.2A priority patent/EP1729768B1/en
Publication of WO2005089317A2 publication Critical patent/WO2005089317A2/en
Publication of WO2005089317A3 publication Critical patent/WO2005089317A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Pharmaceutical formulations including an immune response modifier (IRM) compound having a 2-aminopyridine moiety fused to a five-membered nitrogen-containing heterocyclic ring; a preservative system including a sorbic acid preservative selected from the group consisting of sorbic acid, esters thereof, salts thereof, and combinations thereof; an antioxidant; and an optional chelating agent.
PCT/US2005/008576 2004-03-15 2005-03-14 Immune response modifier formulations and methods WO2005089317A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES05725623.2T ES2665342T3 (en) 2004-03-15 2005-03-14 Formulations and methods for immune response modifiers
US10/598,824 US20070167479A1 (en) 2004-03-15 2005-03-14 Immune response modifier formulations and methods
JP2007504030A JP4991520B2 (en) 2004-03-15 2005-03-14 Immune response modulator formulation and method
CA2559607A CA2559607C (en) 2004-03-15 2005-03-14 Immune response modifier formulations and methods
AU2005222995A AU2005222995B2 (en) 2004-03-15 2005-03-14 Immune response modifier formulations and methods
EP05725623.2A EP1729768B1 (en) 2004-03-15 2005-03-14 Immune response modifier formulations and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55314804P 2004-03-15 2004-03-15
US60/553,148 2004-03-15

Publications (2)

Publication Number Publication Date
WO2005089317A2 WO2005089317A2 (en) 2005-09-29
WO2005089317A3 true WO2005089317A3 (en) 2006-07-27

Family

ID=34994263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/008576 WO2005089317A2 (en) 2004-03-15 2005-03-14 Immune response modifier formulations and methods

Country Status (7)

Country Link
US (1) US20070167479A1 (en)
EP (1) EP1729768B1 (en)
JP (1) JP4991520B2 (en)
AU (1) AU2005222995B2 (en)
CA (1) CA2559607C (en)
ES (1) ES2665342T3 (en)
WO (1) WO2005089317A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2536136C (en) 2003-08-27 2012-10-30 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP5043435B2 (en) 2003-10-03 2012-10-10 スリーエム イノベイティブ プロパティズ カンパニー Alkoxy substituted imidazoquinolines
NZ546274A (en) 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
AR046781A1 (en) 2003-11-25 2005-12-21 3M Innovative Properties Co IMIDAZOQUINOLINE DERIVATIVES. PHARMACEUTICAL COMPOSITIONS.
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006074003A2 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
JP2008526765A (en) 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー Treatment of skin metastases
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
US8178677B2 (en) 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
AU2006216799A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
JP2008531567A (en) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド Hydroxyalkyl-substituted imidazoquinoline compounds and methods
MX2007011112A (en) * 2005-03-14 2007-11-07 Graceway Pharmaceuticals Llc Method of treating actinic keratosis.
EA200800782A1 (en) 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. AMIDA AND CARBAMATE DERIVATIVES N- {2- [4-AMINO-2- (ETOXIMETHYL) -1H-IMIDAZOLO [4,5-c] QUINOLIN-1-IL] -1,1-DIMETHYLETHYL} METHANE SULFONAMIDE AND METHODS
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
JP5247458B2 (en) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
HUE033901T2 (en) 2010-08-17 2018-01-29 3M Innovative Properties Co Lipidated immune response modifier compound compositions, formulations, and methods
BR112013031039B1 (en) 2011-06-03 2020-04-28 3M Innovative Properties Co hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate
JP6460789B2 (en) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
WO2019195802A1 (en) * 2018-04-05 2019-10-10 Bausch Health Ireland Limited Polymeric emulsion delivery systems
US11891588B2 (en) 2019-07-31 2024-02-06 Ecolab Usa Inc. Personal protective equipment free delimer compositions o

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US6194425B1 (en) * 1997-12-11 2001-02-27 3M Innovative Properties Company Imidazonaphthyridines
US6245776B1 (en) * 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US664260A (en) * 1897-09-29 1900-12-18 William Hamlin Manufacture of starch.
US3906108A (en) * 1973-10-12 1975-09-16 Johnson & Johnson Stabilized tretinoin cream emulsion
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US5721275A (en) * 1989-06-07 1998-02-24 Bazzano; Gail S. Slow release vehicles for minimizing skin irritancy of topical compositions
SE464167B (en) * 1989-07-31 1991-03-18 Analytecon Sa TOPICAL PHARMACEUTICAL PREPARATION OF PODOPHYLLOTOXIN
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5079001A (en) * 1989-11-03 1992-01-07 Ciba-Geigy Corporation Liquid oral formulation of diclofenac
US5583136A (en) * 1990-01-29 1996-12-10 Johnson & Johnson Consumer Products, Inc. Retinoid containing skin care compositions containing imidazoles
DK0453603T3 (en) * 1990-04-26 1993-11-22 Com Pharm Arzneimittel Gmbh Piroxicam-containing pharmaceutical preparations for topical use
ES2071340T3 (en) * 1990-10-05 1995-06-16 Minnesota Mining & Mfg PROCEDURE FOR THE PREPARATION OF IMIDAZO (4,5-C) QUINOLIN-4-AMINAS.
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
JP3313148B2 (en) * 1992-07-13 2002-08-12 株式会社資生堂 External preparation for skin
ATE365530T1 (en) * 1992-07-13 2007-07-15 Shiseido Co Ltd STABILIZED SKIN CARE PRODUCT CONTAINING RETINOL FOR EXTERNAL USE
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
JPH09500128A (en) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー Imidazo [4,5-c] pyridin-4-amine
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
DE4345186C2 (en) * 1993-12-27 1997-08-14 Galderma Sa Hydrocortisone 21-acetate-17-propionate containing W / O lotions
US6080393A (en) * 1994-07-09 2000-06-27 Johnson & Johnson Consumer Products, Inc. Skin care composition comprising a retinoid
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US6039969A (en) * 1996-10-25 2000-03-21 3M Innovative Properties Company Immune response modifier compounds for treatment of TH2 mediated and related diseases
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4101302B2 (en) * 1997-01-09 2008-06-18 テルモ株式会社 Novel amide derivatives and synthetic intermediates
DE19701018A1 (en) * 1997-01-14 1998-10-15 Basf Ag Aqueous preparations and their use
US6007846A (en) * 1997-05-16 1999-12-28 Townley Jewelry, Inc. Scented body gel having particulate matter in the form of glitter with predetermined shapes
US6200605B1 (en) * 1997-10-30 2001-03-13 Charles E. Day Antiflatulent composition
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
AU1044500A (en) * 1998-11-03 2000-05-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazonaphthyridines
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6231849B1 (en) * 1999-03-25 2001-05-15 George A. Schiller Simulated seminal fluid
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US6372791B1 (en) * 2000-06-29 2002-04-16 Johnson & Johnson Consumer Companies, Inc. Method of promoting skin cell metabolism
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US20020110840A1 (en) 2000-12-08 2002-08-15 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
JP2005501550A (en) * 2001-08-30 2005-01-20 スリーエム イノベイティブ プロパティズ カンパニー Maturation of plasmacytoid dendritic cells using immune response modifier molecules
JP3685121B2 (en) * 2001-10-29 2005-08-17 神鋼鋼線工業株式会社 Transparent protective tube for outer cable
DE60230340D1 (en) * 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2541132T3 (en) * 2002-02-22 2015-07-16 Meda Ab Method to reduce and treat UV-B-induced immunosuppression
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
MXPA04012199A (en) * 2002-06-07 2005-02-25 3M Innovative Properties Co Ether substituted imidazopyridines.
EP1545597B1 (en) * 2002-08-15 2010-11-17 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
AU2003299082A1 (en) * 2002-09-26 2004-04-19 3M Innovative Properties Company 1h-imidazo dimers
WO2004058759A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
CA2517528A1 (en) * 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
EP1605943A4 (en) * 2003-03-07 2008-01-16 3M Innovative Properties Co 1-amino 1h-imidazoquinolines
US7699057B2 (en) 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
CA2518282C (en) 2003-03-13 2012-11-06 3M Innovative Properties Company Methods of improving skin quality
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US6194425B1 (en) * 1997-12-11 2001-02-27 3M Innovative Properties Company Imidazonaphthyridines
US6245776B1 (en) * 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Also Published As

Publication number Publication date
CA2559607C (en) 2013-02-19
ES2665342T3 (en) 2018-04-25
AU2005222995B2 (en) 2010-08-26
JP2007529537A (en) 2007-10-25
AU2005222995A1 (en) 2005-09-29
CA2559607A1 (en) 2005-09-29
EP1729768B1 (en) 2018-01-10
WO2005089317A2 (en) 2005-09-29
EP1729768A2 (en) 2006-12-13
US20070167479A1 (en) 2007-07-19
EP1729768A4 (en) 2013-10-30
JP4991520B2 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
WO2005089317A3 (en) Immune response modifier formulations and methods
IL278766B1 (en) Molecule, n-(3-chloro-1-(pyridin-3-yl)-1h-pyrazol-4-yl)-2- (methylsulfonyl)propanamide, having pesticidal utility
WO2007028135A3 (en) Imidazopyridine compounds
WO2007067836A3 (en) Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
WO2005110013A3 (en) Methods, compositions, and preparations for delivery of immune response modifiers
WO2006069155A3 (en) Inhibitors of protein arginine methyl transferases
WO2006091457A3 (en) Ionic liquids derived from peracid anions
RS54904B1 (en) Antibacterial pharmaceutical compositions
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2002020489A3 (en) QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE
CY2013023I1 (en) DRUG FOR OVERACTIVE URINARY BLADDER CONTAINING ACETIC ACID ANALYDE DERIVATIVE AS THE ACTIVE INGREDIENT
WO2008085570A3 (en) Flux formulations
WO2008096829A1 (en) Tricyclic compounds
WO2006000371A3 (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
RS53999B1 (en) A pyridin quinolin substituted pyrrolo (1,2-b) pyrazole monohydrate as tgf-beta inhibtor
WO2007092642A3 (en) Polymer formulations of cetp inhibitors
DK1268471T3 (en) N-heterocyclic derivatives as NOS inhibitors
WO2006005726A3 (en) Heterocyclic compounds
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
WO2005100368A3 (en) Stable amorphous cefdinir
WO2007025880A3 (en) Pyrazolone derivatives as 11-beta hsd1 inhibitors
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2008126901A1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
RS52515B (en) Fast dissociating dopamine 2 receptor antagonists
EP1479684A4 (en) Thienopyrimidines, process for preparing the same and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2007167479

Country of ref document: US

Ref document number: 10598824

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2559607

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007504030

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005222995

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005725623

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005222995

Country of ref document: AU

Date of ref document: 20050314

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005222995

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005725623

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10598824

Country of ref document: US